Effects in broiler hens of genetic lines differing in fertility, biotin supplementation, and age on relative abundance of oviductal transforming growth factor-beta and carbonic anhydrase mRNA transcripts
ANIMAL REPRODUCTION SCIENCE
Authors: Rostami, S.; Akhlaghi, A.; Ahangari, Y. Jafari; Pirsaraei, Z. Ansari; Daryabari, H.; Zahedi, M. R.; Bagheri, M.; Rafiee, P.; Zhandi, M.; Eghbalian, A. N.; Saemi, F.; Peebles, E. D.
Abstract
There was evaluation of effects of biotin administration on oviductal abundance of transforming growth factor-beta (TGF-beta) and carbonic anhydrase (CA) mRNA transcript in younger and older broiler hens of relatively lesser and greater fertility lines. Additionally, effects of biotin supplementation on attenuation of age-related subfertility were evaluated. Hens from the relatively greater (Line D, n = 60) and lesser (Line B, n = 60) fertility rate line were randomly assigned to three treatment groups. Biotin was not or was administered in drinking water from 30 to 33 (younger age) and 53 to 56 (older age) wk of age to have access to no biotin (T-0), or 0.3 (T-1), or 0.45 (T-2) mg/L of biotin. There was assessment the relative oviductal abundances of TGF-beta and CA mRNA transcript abundances. Supplemental biotin and age had no effect on the relative abundance of oviductal TGF-beta mRNA transcript in hens of Line D. There, however, was a ten-fold greater abundance of TGF-beta in hens of the T-0 group of Line B compared with Line D. Relative abundance of TGF-beta mRNA transcript was greater in younger hens of Line B; however, biotin supplementation of older hens of the T-2 group of Line B resulted in a similar TGF-beta abundance to that of younger hens. Inconstant with the TGF-beta abundance, CA abundance in hens of Line B was not affected by supplemental biotin or bird age. Overall, differences in TGF-beta or CA abundances did not affect fertility of broiler hens.
Investigating complement mediated interference in class I HLA-specific antibodies following renal transplantation
TRANSPLANT IMMUNOLOGY
Authors: Goldsmith, Petra; Lowe, David; Wong, Chang; Howse, Matthew; Ridgway, Dan; Hammad, Abdul; Mehra, Sanjay; Christmas, Steve; Gebel, Howard; Bray, Robert; Jones, Andrew
Abstract
Introduction: Single antigen bead testing (SAB) for HLA-specific antibody enables efficient organ allocation and aids in the diagnosis of antibody mediated rejection. In this retrospective cohort study, a population of kidney transplant recipients possessing HLA Class I antibodies was used to evaluate the best method for resolving complement interference, the so called "prozone" effect. The aim was to compare the use of EDTA versus a Biotin-Streptavidin Complex as methodological approaches for abating the prozone effect using a fixed 1 in 10 dilution as validation. Methods: One hundred and seventeen patients transplanted in our centre between 2009 and 2014 were identified as having class I HLA-specific antibody(-ies) using a Labscreen (R) Mixed assay. Positive sera underwent class I HLA-specific SAB testing; for comparison a standard SAB with and without EDTA, BSC and dilution (1 in 10) modifications were utilised. Samples were processed on the Luminex platform generating 11,349 bead reactions for analysis. Results: We identified sera from 23 patients giving rise to 170 bead reactions showing complement interference. Using linear modelling, we observed slightly higher MFIs on average in both EDTA and BSC modifications when compared to the standard assay, allowing the nominal threshold MFI of 2000 in the standard assay to be adjusted to 2097 and 2033 in the EDTA and BSC assays respectively. We calculated 99% prediction intervals to establish outlier bead reactions for each assay. The 1 in 10 dilution was used as a crosscheck for determining which prozone reactions were overcome by EDTA and BSC. Using ROC curve analysis, EDTA was found to be similar to 90% sensitive and 100% specific compared to BSC which was similar to 60% sensitive and 100% specific in ameliorating prozone positive reactions at the thresholds defined by linear models. Discussion: Our data indicates that both EDTA and BSC are suitable assays in overcoming CMI. We recommend that all clinical laboratories adopt a validated assay designed specifically to abrogate CMI for all potential renal transplant recipients, as the standard assay is inhibited in nearly 20% of a post-transplant cohort.